Cite
HARVARD Citation
Piha-Paul, S. et al. (n.d.). A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. European journal of cancer. pp. S17-S18. [Online].